Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.
Eli Lilly and Company (NYSE:LLY) traded higher Friday after new late-stage trial data highlighted significant weight reduction in older adults using Foundayo.
The drugmaker presented updated analyses from its Phase 3 ATTAIN studies during the European Congress on Obesity in Istanbul.
Something went wrong.
According to a press release, the oral GLP-1 treatment delivered double-digit weight loss in some patients aged 65 and older.
Older Adults Show Strong Weight Reduction
Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.
Lilly says Foundayo was approved to treat obesity and can lead to long-term weight loss, alongside diet and exercise.
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…
Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.
The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss.
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the…
Pharmalittle: We're reading about a Lilly obesity drug trial, statistics for an Alzheimer's drug, and more
Lilly’s triple agonist still leads among late-stage obesity assets
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
New weight-loss shot more powerful than old GLP-1s, Eli Lilly says
Eli Lilly says next-gen obesity drug helps patients lose 28% of body weight
